Evidence map›Paper›PMID 26998132›Full record

ArticleOncology letters2016

A novel

Moneeb A K Othman, Beata Grygalewicz, Barbara Pienkowska-Grela, Jolanta Rygier, Anna Ejduk, Martina Rincic, Joana B Melo, Isabel M Carreira, Britta Meyer, Thomas Liehr

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. International journal of molecular sciences · 2025
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Moneeb A K OthmanInstitute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Jena D-07740, Germany.
Beata GrygalewiczCytogenetic Laboratory, Maria Sklodowska-Curie Memorial Cancer Centre and Institute, Warsaw 02-781, Poland.
Barbara Pienkowska-GrelaCytogenetic Laboratory, Maria Sklodowska-Curie Memorial Cancer Centre and Institute, Warsaw 02-781, Poland.
Jolanta RygierCytogenetic Laboratory, Maria Sklodowska-Curie Memorial Cancer Centre and Institute, Warsaw 02-781, Poland.
Anna EjdukDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw 02-776, Poland.
Martina RincicInstitute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Jena D-07740, Germany; Croatian Institute of Brain Research, Zagreb 10000, Croatia, Germany.
Joana B MeloLaboratory of Cytogenetics and Genomics, Faculty of Medicine, University of Coimbra, Coimbra 3001-401, Portugal; Research Centre for Environment, Genetics and Oncobiology, Faculty of Medicine, University of Coimbra, Coimbra 3001-401, Portugal, Germany.
Isabel M CarreiraLaboratory of Cytogenetics and Genomics, Faculty of Medicine, University of Coimbra, Coimbra 3001-401, Portugal; Research Centre for Environment, Genetics and Oncobiology, Faculty of Medicine, University of Coimbra, Coimbra 3001-401, Portugal, Germany.
Britta MeyerZytoVision GmbH, Bremerhaven D-27572, Germany.
Thomas LiehrInstitute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Jena D-07740, Germany.
The Maria Sklodowska-Curie National Research Institute of Oncology · PLFriedrich Schiller University Jena · DEUniversity of Coimbra · PTInstytut Hematologii i Transfuzjologi · PLJena University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired copy number changes are common in acute leukemia. They are reported as recurrent amplifications or deletions (del), and may be indicative of involvement of oncogenes or tumor suppressor genes in acquired disease, as well as serving as potential biomarkers for prognosis or as targets for molecular therapy. The present study reported a gain of copy number of 14q13 to 14q32, leading to immunoglobulin heavy chain locus splitting in a young adult female. To the best of our knowledge, this rearrangement has not been previously reported in B-cell acute lymphoblastic leukemia (ALL). Low resolution banding cytogenetics performed at the time of diagnosis revealed a normal karyotype. However, retrospective application of fluorescence

Indexed as

array-comparative genomic hybridizationB-cell acute lymphoblastic leukemiacyclin-dependent kinase inhibitor 2A/B deletionimmunoglobulin heavy locus gene rearrangementmolecular cytogenetics

Identifiers

PMID26998132
PMCPMC4774591
OpenAlexW2254036805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.